Correction of Ornithine Transcarbamylase Deficiency in AdultspfashMice and in OTC-Deficient Human Hepatocytes with Recombinant Adenoviruses Bearing the CAG Promoter
- 1 May 1996
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 7 (7) , 821-830
- https://doi.org/10.1089/hum.1996.7.7-821
Abstract
Ornithine transcarbamylase (OTC) deficiency, the most common and severe inborn error of the urea cycle in humans, remains without adequate treatment, and mortality rates are high. Adenoviral vectors provide an efficient system for gene delivery, but there are problems, including toxicity. Efficient promoters that reduce the amount of vector required for treatment need to be developed. We constructed two recombinant adenoviral vectors, AdexCAGhOTC and AdexSRαhOTC, which harbor the human OTC gene under transcriptional control of CAG (a modified chicken β-actin promoter with CMV-IE enhancer) and SRα (the SV40 early promoter with the R segment and part of the U5 segment of the HTLV-1 LTR), respectively. Each was tested in adult spfash mice, an animal model of human OTC deficiency, and in primary human hepatocytes with OTC deficiency. Spfash mice have a pronounced orotic aciduria as seen in humans. A complete recovery of hepatic OTC activity with minimal tissue damage was observed in these animals following the intravenous administration of AdexCAGhOTC alone. Western blot analysis confirmed hepatic OTC expression and normalization of orotic aciduria was evident for 60 days. Enzyme activities of primary human hepatocytes infected with AdexCAGhOTC were 10–40 times higher than those with AdexSRαhOTC. Thus, the adenoviral vector with an efficient promoter such as CAG, can be given further consideration for possible gene therapy in humans with OTC deficiency. Kiwaki et al. report the adenoviral-mediated transfer of the ornithine transcarbamylase (OTC) gene. Using the CAG promoter, enzyme activity equal to that of the wild type was obtained in adult spfash mice and in deficient human hepatocytes. The strong and rapid expression seen here would be advantageous for treating subjects with this disease. The immune response would need to be given further study.Keywords
This publication has 38 references indexed in Scilit:
- Safety and efficacy of repetitive adenovirus–mediated transfer of CFTR cDNA to airway epithelia of primates and cotton ratsNature Genetics, 1994
- Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery.Journal of Clinical Investigation, 1993
- Efficient selection for high-expression transfectants with a novel eukaryotic vectorGene, 1991
- Correction of ornithine transcarbamylase (OTC) deficiency in spf-ash mice by introduction of rat OTC geneFEBS Letters, 1991
- Late-onset ornithine transcarbamylase deficiency in male patientsThe Journal of Pediatrics, 1990
- Natural History of Symptomatic Partial Ornithine Transcarbamylase DeficiencyNew England Journal of Medicine, 1986
- Biochemical heterogeneity of ornithine carbamoyl transferase(OCT) in patients with OCT deficiencyJournal of Human Genetics, 1984
- Neurologic Outcome in Children with Inborn Errors of Urea SynthesisNew England Journal of Medicine, 1984
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970
- Gene Action in the X-chromosome of the Mouse (Mus musculus L.)Nature, 1961